Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy

Asia Pac J Clin Oncol. 2024 Apr;20(2):180-187. doi: 10.1111/ajco.13961. Epub 2023 May 12.

Abstract

Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC.

Keywords: adverse effects; esophageal cancer; immunotherapy; prognosis.

Publication types

  • Review

MeSH terms

  • Esophageal Neoplasms* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors* / adverse effects
  • Immunotherapy / adverse effects

Substances

  • Immune Checkpoint Inhibitors